Get the Stockscreener App
4.03
0.50%
0.02
After Hours:
4.04
0.010
+0.25%
Ataibeckley Inc stock is traded at $4.03, with a volume of 3.85M.
It is up +0.50% in the last 24 hours and up +7.18% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$4.01
Open:
$4.03
24h Volume:
3.85M
Relative Volume:
0.68
Market Cap:
$1.48B
Revenue:
$4.09M
Net Income/Loss:
$-660.15M
P/E Ratio:
-1.7481
EPS:
-2.3053
Net Cash Flow:
$-117.10M
1W Performance:
-2.66%
1M Performance:
+7.18%
6M Performance:
-7.57%
1Y Performance:
+187.86%
1-Day Range:
$3.945
$4.075
1-Week Range:
$3.90
$4.275
52-Week Range:
$1.375
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
4.03 | 1.47B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.34B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.96B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.51B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.89B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
AtaiBeckley Inc. (ATAI) Stock Analysis: Unveiling a Potential 249% Upside in the Biotech Sector - DirectorsTalk Interviews
These stocks are today’s movers: Fermi, AST SpaceMobile, Intel, Marvell, USA Rare Earth, Ataibeckley, and more - MSN
ATAI stock soars on track for best day on Trump psychedelics push and Wall Street cheers - MSN
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
Is AtaiBeckley (ATAI) Redefining Its Psychedelic Strategy With Standalone EMP-01 Anxiety Data? - simplywall.st
10 Health Care Stocks With Whale Alerts In Today's SessionAbbVie (NYSE:ABBV), AtaiBeckley (NASDAQ:ATAI - Benzinga
Does AtaiBeckley’s (ATAI) EMP-01 Data Hint At A Scalable MDMA Therapy Platform? - Yahoo Finance
Ataibeckley: Anxiety drug cuts social phobia symptoms by 38% - MSN
ATAI Stock Price, Quote & Chart | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Why Ataibeckley stock surged today - MSN
Atai Beckley N.V. (ATAI) Receives a Buy from H.C. Wainwright - The Globe and Mail
AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg - MSN
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug - MSN
H.C. Wainwright Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Psychedelic stocks soar as Trump signs order to ease access - MSN
Small cap wrap: VivoPower, First Phosphate, ataiBeckley, Trillion Energy... - Proactive financial news
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials - Proactive Investors
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research - Investing News Network
AtaiBeckley and PsyPAN win silver for trial participant input - Stock Titan
Enveric Biosciences surges over 90%, other psychedelic stocks soar in Monday pre-market: What's going on? - MSN
AtaiBeckley Inc.Common Stock (NQ: ATAI - The Chronicle-Journal
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):